393 related articles for article (PubMed ID: 18579718)
1. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.
Pfaller MA; Diekema DJ; Ostrosky-Zeichner L; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
J Clin Microbiol; 2008 Aug; 46(8):2620-9. PubMed ID: 18579718
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
3. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
5. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
[TBL] [Abstract][Full Text] [Related]
6. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?
Espinel-Ingroff A; Arendrup MC; Pfaller MA; Bonfietti LX; Bustamante B; Canton E; Chryssanthou E; Cuenca-Estrella M; Dannaoui E; Fothergill A; Fuller J; Gaustad P; Gonzalez GM; Guarro J; Lass-Flörl C; Lockhart SR; Meis JF; Moore CB; Ostrosky-Zeichner L; Pelaez T; Pukinskas SR; St-Germain G; Szeszs MW; Turnidge J
Antimicrob Agents Chemother; 2013 Dec; 57(12):5836-42. PubMed ID: 24018263
[TBL] [Abstract][Full Text] [Related]
7. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
8. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
[TBL] [Abstract][Full Text] [Related]
9. Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.
Eschenauer GA; Nguyen MH; Shoham S; Vazquez JA; Morris AJ; Pasculle WA; Kubin CJ; Klinker KP; Carver PL; Hanson KE; Chen S; Lam SW; Potoski BA; Clarke LG; Shields RK; Clancy CJ
Antimicrob Agents Chemother; 2014; 58(4):1897-906. PubMed ID: 24395235
[TBL] [Abstract][Full Text] [Related]
10. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Jones RN; Turnidge J; Diekema DJ
J Clin Microbiol; 2010 Jan; 48(1):52-6. PubMed ID: 19923478
[TBL] [Abstract][Full Text] [Related]
11. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
12. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
13. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
14. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin.
Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskov A; Ramani R
J Clin Microbiol; 2008 Jul; 46(7):2155-9. PubMed ID: 18463213
[TBL] [Abstract][Full Text] [Related]
16. Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
[TBL] [Abstract][Full Text] [Related]
17. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Moet GJ; Jones RN
J Clin Microbiol; 2010 May; 48(5):1592-9. PubMed ID: 20335424
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.
Fleischhacker M; Radecke C; Schulz B; Ruhnke M
Eur J Clin Microbiol Infect Dis; 2008 Feb; 27(2):127-31. PubMed ID: 18057972
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro susceptibility of clinical isolates of Candida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest.
Khan Z; Ahmad S; Joseph L; Chandy R; Theyyathel A
J Chemother; 2011 Apr; 23(2):97-101. PubMed ID: 21571626
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
